Oncology

At Johnson & Johnson Innovative Medicine (J&J), we innovate with purpose to lead where medicine is going.

We work every day to get in front of cancer, convening the brightest minds to create, nurture and deliver new approaches to detect, intercept and one day eliminate this disease.

We are driven by a bold vision to eliminate cancer

Our oncology legacy

With more than three decades of history in oncology our commitment to pioneer new therapeutic advances and continue redefining treatment paradigms in haematologic malignancies and solid tumours is stronger than ever.

We remain laser-focused on transforming the way cancer is treated and managed, to ultimately get in front of cancer.”

Dr John Fleming

Country Medical Director, Johnson & Johnson Innovative Medicine, UK.

Where we are now

J&J is focused in areas where patient need is high and our expertise is deep – this includes multiple myeloma, B-cell malignancies, lung cancer, prostate cancer and other areas of high unmet need within genitourinary oncology.

We take part in collaborative working projects with the NHS to support the delivery of solutions that provide value to patients, healthcare professionals and the health system itself.

Our oncology areas of focus